JP2017517538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517538A5 JP2017517538A5 JP2016572302A JP2016572302A JP2017517538A5 JP 2017517538 A5 JP2017517538 A5 JP 2017517538A5 JP 2016572302 A JP2016572302 A JP 2016572302A JP 2016572302 A JP2016572302 A JP 2016572302A JP 2017517538 A5 JP2017517538 A5 JP 2017517538A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- ring
- pyridazin
- imidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- MPNAKLGQWGUYOO-UHFFFAOYSA-N 3-[5-(7-ethylimidazo[4,5-c]pyridazin-4-yl)-2-fluorophenyl]-5-fluoro-N-methylbenzamide Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC(=CC(=C1)F)C(=O)NC)F MPNAKLGQWGUYOO-UHFFFAOYSA-N 0.000 claims 1
- JMXQSRJJPVLGLQ-UHFFFAOYSA-N 3-[5-(7-ethylimidazo[4,5-c]pyridazin-4-yl)-2-fluorophenyl]benzamide Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC(=CC=C1)C(=O)N)F JMXQSRJJPVLGLQ-UHFFFAOYSA-N 0.000 claims 1
- ZBZGITBHHLRNSX-UHFFFAOYSA-N 5-[2-fluoro-5-(7-propan-2-ylimidazo[4,5-c]pyridazin-4-yl)phenyl]-2-methyl-3H-isoindol-1-one Chemical compound FC1=C(C=C(C=C1)C=1C2=C(N=NC=1)N(C=N2)C(C)C)C=1C=C2CN(C(C2=CC=1)=O)C ZBZGITBHHLRNSX-UHFFFAOYSA-N 0.000 claims 1
- AZSCZGPLVZULKG-UHFFFAOYSA-N 5-[5-(7-ethylimidazo[4,5-c]pyridazin-4-yl)-2-fluorophenyl]-2-methyl-3H-isoindol-1-one Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C=1C=C2CN(C(C2=CC=1)=O)C)F AZSCZGPLVZULKG-UHFFFAOYSA-N 0.000 claims 1
- XPSAGIQSESMIJK-UHFFFAOYSA-N 5-[5-(7-ethylimidazo[4,5-c]pyridazin-4-yl)-2-fluorophenyl]-6-methoxy-2-methyl-3H-isoindol-1-one Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C=1C=C2CN(C(C2=CC=1OC)=O)C)F XPSAGIQSESMIJK-UHFFFAOYSA-N 0.000 claims 1
- CHIRBXJNJJPPBZ-UHFFFAOYSA-N 6-[5-(7-ethylimidazo[4,5-c]pyridazin-4-yl)-2-fluorophenyl]-2-methyl-3H-isoindol-1-one Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC=C2CN(C(C2=C1)=O)C)F CHIRBXJNJJPPBZ-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011137P | 2014-06-12 | 2014-06-12 | |
| US62/011,137 | 2014-06-12 | ||
| PCT/IB2015/054200 WO2015189744A1 (en) | 2014-06-12 | 2015-06-03 | Imidazopyridazine derivatives as modulators of the gabaa receptor activity. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017517538A JP2017517538A (ja) | 2017-06-29 |
| JP2017517538A5 true JP2017517538A5 (cg-RX-API-DMAC7.html) | 2018-07-12 |
| JP6491679B2 JP6491679B2 (ja) | 2019-03-27 |
Family
ID=53434408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572302A Active JP6491679B2 (ja) | 2014-06-12 | 2015-06-03 | Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9802945B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3154979B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6491679B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2951497C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2664810T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015189744A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391708B (es) | 2015-07-17 | 2025-03-21 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo con gaboxadol. |
| EP3386983A1 (en) * | 2015-12-10 | 2018-10-17 | Pfizer Limited | 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain |
| CN109328205B (zh) * | 2016-06-28 | 2021-02-05 | 东丽株式会社 | 环氧树脂组合物、预浸料坯及纤维增强复合材料 |
| KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| WO2019028234A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS |
| CN118141810A (zh) * | 2019-07-15 | 2024-06-07 | 奥维德医疗公司 | 用于治疗性治疗的包含加波沙朵的药物制剂 |
| JP7765386B2 (ja) * | 2019-10-21 | 2025-11-06 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 発達障害の予防、軽減又は治療のためのイミダゾピリミジン又はイミダゾトリアジン化合物の使用 |
| TW202128697A (zh) * | 2019-10-22 | 2021-08-01 | 美商紐羅塞克醫療公司 | Gabaa正向別構調節劑化合物、其製備方法及用途 |
| US20230020036A1 (en) * | 2019-10-23 | 2023-01-19 | Neurocycle Therapeutics, Inc. | Treatment of epileptic conditions with gabaa receptor modulators |
| CN116693555B (zh) * | 2022-02-25 | 2025-07-04 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途 |
| WO2023213198A1 (zh) * | 2022-05-04 | 2023-11-09 | 华东师范大学 | 芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂 |
| CN117069725A (zh) | 2022-05-10 | 2023-11-17 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
| GB9921150D0 (en) * | 1999-09-07 | 1999-11-10 | Merck Sharp & Dohme | Therapeutic agents |
| GB0117277D0 (en) | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
| ATE310740T1 (de) | 2000-11-10 | 2005-12-15 | Merck Sharp & Dohme | Imidazotriazin-derivate als liganden für gaba- rezeptoren |
| US20080132510A1 (en) | 2005-01-21 | 2008-06-05 | Bingsong Han | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives |
| ATE461177T1 (de) | 2007-03-23 | 2010-04-15 | Icagen Inc | Ionenkanal-hemmer |
| PL2385938T3 (pl) | 2009-01-12 | 2015-07-31 | Pfizer Ltd | Pochodne sulfonamidu |
| CN102574830A (zh) | 2009-05-07 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 取代的1-氰基乙基杂环基甲酰胺化合物750 |
| UA112028C2 (uk) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
-
2015
- 2015-06-03 EP EP15730284.5A patent/EP3154979B1/en not_active Not-in-force
- 2015-06-03 US US15/316,552 patent/US9802945B2/en active Active
- 2015-06-03 CA CA2951497A patent/CA2951497C/en not_active Expired - Fee Related
- 2015-06-03 WO PCT/IB2015/054200 patent/WO2015189744A1/en not_active Ceased
- 2015-06-03 ES ES15730284.5T patent/ES2664810T3/es active Active
- 2015-06-03 JP JP2016572302A patent/JP6491679B2/ja active Active